Disgruntled long term holders, page-5

I'm not sure that 4 follows from 3

After all, a lot of the issues to do with scale-up are sorted out. I think the biggest single expense, by a long margin, sill be the Ph III trial and all the ancillary issues will be at least an order of magnitude cheaper.

So if you work on the premise that the company does its own Ph III, and it's successful, why sell out? Why not just go to market themselves?

I still think it most likely Ph III will be partnered.